Murex patent infringement claims against Abbott focus on IMx, AxSYM systems.
This article was originally published in The Gray Sheet
MUREX ALLEGES PATENT INFRINGEMENT BY ABBOTT IMx AND AxSYM ANALYZERS in a complaint filed July 1 in the U.S. District Court for the Northern District of Georgia, Atlanta. Murex Diagnostics, a division of International Murex Ltd., says a filtration process used in Abbott's diagnostic analyzers infringes the Marshall Patent, No. 5,501,949, which was issued to Murex on March 26. Murex says that on March 28, it informed Abbott of the '949 patent and told Abbott that it believes the IMx Immunoassay and AxSYM System infringe certain claims of the patent.
You may also be interested in...
While endocrine-disrupting evidence was inconclusive, the Scientific Committee on Consumer Safety recommends more conservative limits on use of homosalate, octocrylene and benzophenone-3 in cosmetic products compared with current requirements under the European Cosmetics Product Regulation.
The risk of inadvertently growing SARS-CoV-2 virus in cell and gene therapies and possibly infecting patients and workers should be assessed and mitigated, the agency advises.
Move was meant to preempt others’ efforts to secure the next six months of Regeneron’s COVID-19 antibody therapeutic.